Immunogenicity of hepatitis <scp>B</scp> vaccine in patients with inflammatory bowel disease and the benefits of revaccination

Cossio-Gil, Yolima; Martínez‐Gómez, Xavier; Campins-Martí, Magda; Rodrigo-Pendás, José Ángel; Borruel, Natalia; Rodríguez‐Frías, Francisco; Casellas, Francesc

doi:10.1111/jgh.12712

Cited by 32 publications

(31 citation statements)

References 35 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two diseases do not seem to differ with respect to immune response to HBV vaccine both in our study and other studies. 14 , 19 , 21 IBD disease location had no significant effect on immune response to HBV in our study. There was no relationship between disease location and immune response in CD, but there was a significant difference between CD subtypes.…”

Section: Discussioncontrasting

confidence: 56%

“…Immune response rates obtained with HBV vaccination in IBD are known to be lower compared with healthy populations, but different results were reported from a few studies on this subject (Altunöz 76%, Gisbert 41%, and Cossio-Gil 50%). 14 , 18 , 19 These different results may be explained by the different characteristics of the patient groups across studies with regards to factors that are influential on immune response including immunosuppressive therapy (IST) and disease activity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Factors Associated With Response to Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

et al. 2015

View full text Add to dashboard Cite

It is recommended to investigate the serology of hepatitis B virus (HBV) and vaccinate seronegative patients at the time of diagnosis in inflammatory bowel diseases (IBD). This study aimed to investigate the efficacy of HBV vaccine and factors affecting the response.In this retrospective, observational study, HBV-seronegative IBD patients were administered 3 doses (at months 0, 1, and 6) recombinant 20 μg HbsAg. Patients’ demographics, IBD attributes, and treatment methods were investigated as the factors with potential impacts on vaccination outcomes.One hundred twenty-five patients with IBD were evaluated. The number of patients with Anti-HBs >10 IU/L was 71 (56.8%), and the number of patients with anti-HBs >100 IU/L was 50 (40%). Age, disease activity, Crohn disease subtype, and immunosuppressive treatment (IST) were found to have significant effects on immune response (P = 0.011, P < 0.001, P = 0.003, and P < 0.001, respectively). With multivariate analysis, age < 45 years (OR 3.1, 95% CI 1.2–8.3, P = 0.020), vaccination during remission (OR 5.6, 95% CI 2.3–14, P < 0.001), and non-IST (OR 11.1, 95% CI 2.9–43.2, P = 0.001) had favorable effects on the occurrence of adequate vaccine response.The likelihood of achieving adequate immune response with standard HBV vaccination protocol in IBD is low. Selecting vaccination protocols with more potent immunogenicity is a better approach to achieve effective vaccine response in patients with multiple unfavorable factors.

show abstract

Section: Discussioncontrasting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Evaluation of Factors Associated With Response to Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This deserves further studies because such individuals are children or younger adults. Several earlier studies have already demonstrated that individuals with anti-HBs seronegativity would be at increased risks of contracting HBV infections even at 20 years of the vaccination (3334). This is noteworthy in HBV-endemic areas, including Korea, which has also been supported by several published studies.…”

Section: Discussionmentioning

confidence: 99%

A Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program in Korea

Kim

Hong

et al. 2017

J Korean Med Sci

View full text Add to dashboard Cite

The antibody to hepatitis B surface antigen (anti-HBs) seropositivity rate after 3 doses of hepatitis B virus (HBV) vaccination during infancy period is known to be higher than 90%. However, a considerable number of vaccines do not form protective anti-HBs or chronologic decrease of anti-HBs. We retrospectively collected data of HBV serologic test results in 20,738 individuals from 2000 to 2015. After exclusion criteria were applied, 19,072 individuals were included. We analyzed the anti-HBs seropositivity rate, anti-HBs disappearance rate, anti-HBs positive seroconversion rate after receiving a booster vaccine, and the difference in anti-HBs positivity between the 2 groups; group A (born before 2005, while both recombinant vaccines and plasma-derived vaccines were used) and group B (born after 2005, when only recombinant vaccines were used by national regulation). The anti-HBs seropositivity rate was 55.8%, but there was a significant difference in the rate of seropositivity for anti-HBs between the group A and B (53.0% vs. 78.1%, P < 0.001). There was no significant age-adjusted difference in the mean seropositivity rate between the 2 groups (P = 0.058). In addition, the anti-HBs positivity rate was significantly lower in the group A as compared with the group B during infancy (83.1% vs. 92.1%, P < 0.001). A total of 1,106 anti-HBs-positive subjects underwent serologic tests more than twice. Of these, 217 subjects (19.6%) showed anti-HBs disappearance. After booster vaccinations, 87.4% (83/95) achieved seroconversion from seronegative to seropositive. Our results highlight the importance of lifelong protection against HBV and the possible necessity of booster vaccination after adolescent period.

show abstract

“…The indicated vaccinations in older IBD patients include the annual influenza flu vaccine, the pneumococcal vaccine administered at the age of 65, and the zoster vaccine after age 60. Importantly, vaccination is more likely to be associated with a suboptimal response in the elderly, especially in the setting of immune suppression [84][85][86].…”

Section: Vaccinationsmentioning

confidence: 98%

Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly

Taleban

2015

Curr Treat Options Gastro

View full text Add to dashboard Cite

Among inflammatory bowel disease (IBD) patients, 4-12 % is diagnosed after the age of 60. Both the rates of elderly and IBD are increasing worldwide. In older patients, the diagnosis of Crohn's disease (CD) and ulcerative colitis (UC) is made more difficult due to polypharmacy and multimorbidity along with disease processes that mimic IBD. The clinical presentation in older-onset IBD differs from younger patients, and there is minimal disease progression over time. The management of the older IBD patient involves a combination of medical and surgical strategies. Few treatment efficacy studies exist in elderly IBD as most authors have focused on the adverse events related to therapy. A vast number of incident CD and UC cases in elderly have been treated with 5-aminosalicylic acid agents and do not require the use of immune modifying agents or biologics. Many other older IBD patients are prescribed long-term corticosteroids despite guidelines recommending more effective and safer maintenance therapy regimens. Serious infections, malignancy, and drug interactions are the most concerning complications of medical therapy. There are particularly important health care maintenance issues in older IBD patients including vaccinations, colorectal cancer screening, and bone loss prevention.

show abstract

Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination

Cited by 32 publications

References 35 publications

Evaluation of Factors Associated With Response to Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

Evaluation of Factors Associated With Response to Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

A Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program in Korea

Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly

Contact Info

Product

Resources

About